After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

Shorter, nanosecond pulses for treating atrial fibrillation differentiate the company’s approach from existing pulsed field ...

Obstructive sleep apnea is associated with increased atrial fibrillation recurrence after ablation in patients with paroxysmal atrial fibrillation.

Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Intracardiac echocardiography is noninferior to TEE for prevention of thromboembolic complications in patients receiving ablation for AF.

Johnson & Johnson MedTech will be one of several companies set to benefit from a new CMS decision related to pulsed field ...

The latest update is out from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ). Imricor Medical Systems has ...